================================================================================
                    DRUG MANUFACTURING LICENSE
                    FORM 25-D / FORM 28-D
================================================================================

                    FOOD AND DRUG ADMINISTRATION
                    GOVERNMENT OF MAHARASHTRA

--------------------------------------------------------------------------------

                    MANUFACTURING LICENSE
                    (Under the Drugs and Cosmetics Act, 1940)

================================================================================

LICENSE NUMBER: MH/25D/2013/1234

LICENSE CATEGORY: Form 25-D (Drugs other than those specified in Schedules C, C1 and X)
                  Form 28-D (Drugs specified in Schedules C, C1 and X)

--------------------------------------------------------------------------------

LICENSEE DETAILS:

Name:               BIOPHARMA INDUSTRIES LIMITED
CIN:                U24230MH2012PLC234567
License Class:      Manufacturing of Allopathic Drugs

Registered Office:  Plot No. 234-235, MIDC Industrial Area
                    Thane-Belapur Road, Rabale
                    Thane - 400701, Maharashtra

Manufacturing Site: Plot No. 234-235, MIDC Industrial Area
                    Thane-Belapur Road, Rabale
                    Thane - 400701, Maharashtra

Total Built-up Area: 85,000 sq. ft.
Manufacturing Area:  52,000 sq. ft.
Quality Control Lab: 8,000 sq. ft.
Warehouse Area:      15,000 sq. ft.
Administrative Area: 10,000 sq. ft.

--------------------------------------------------------------------------------

LICENSE VALIDITY:

Original Issue Date:    March 15, 2013
Last Renewal Date:      March 15, 2023
Valid Until:            March 14, 2028
Renewal Due By:         January 14, 2028

--------------------------------------------------------------------------------

TECHNICAL STAFF (As Required Under Schedule M):

1. TECHNICAL DIRECTOR / APPROVED TECHNICAL HEAD
   Name:              Dr. Rajendra Mohan Patil
   Qualification:     M. Pharm (Pharmaceutics), Ph.D.
   Registration No.:  MH/27984
   Experience:        22 years in pharmaceutical manufacturing
   Appointment Date:  March 1, 2013
   Status:           Active (Full-time employment)

2. PRODUCTION MANAGER
   Name:              Mr. Suresh Kumar Sharma
   Qualification:     B. Pharm
   Registration No.:  MH/31456
   Experience:        15 years
   Appointment Date:  April 1, 2013
   Status:           Active

3. HEAD OF QUALITY ASSURANCE
   Name:              Mrs. Deepika Sunil Jain
   Qualification:     M. Pharm (Quality Assurance)
   Registration No.:  MH/29876
   Experience:        18 years
   Appointment Date:  March 15, 2013
   Status:           Active

4. HEAD OF QUALITY CONTROL
   Name:              Dr. Anita Prakash Shah
   Qualification:     M.Sc. (Analytical Chemistry), Ph.D.
   Experience:        16 years
   Appointment Date:  March 20, 2013
   Status:           Active

================================================================================

LICENSED MANUFACTURING ACTIVITIES:

This license authorizes the manufacture of the following categories of drugs:

CATEGORY A: TABLETS AND CAPSULES (NON-BETA-LACTAM)

1. Cardiovascular Drugs
   - Antihypertensives (Amlodipine, Losartan, Telmisartan, Atenolol)
   - Antianginals (Isosorbide)
   - Lipid-lowering agents (Atorvastatin, Rosuvastatin)

2. Antidiabetic Drugs
   - Biguanides (Metformin)
   - Sulfonylureas (Glimepiride)
   - DPP-4 Inhibitors (Sitagliptin - under license)

3. Gastrointestinal Drugs
   - Proton Pump Inhibitors (Omeprazole, Pantoprazole, Rabeprazole)
   - H2 Receptor Antagonists (Ranitidine)
   - Prokinetics (Domperidone)

4. Analgesics and Antipyretics
   - Paracetamol
   - Ibuprofen
   - Diclofenac

5. Vitamins and Nutritional Supplements
   - Multivitamins
   - Calcium supplements
   - Iron supplements

6. Respiratory Drugs
   - Antihistamines (Cetirizine, Levocetirizine)
   - Antitussives
   - Bronchodilators (Montelukast)

CATEGORY B: TABLETS AND CAPSULES (BETA-LACTAM - DEDICATED BLOCK)

7. Penicillins (Manufactured in Dedicated Penicillin Block)
   - Amoxicillin
   - Ampicillin
   - Amoxicillin + Clavulanic Acid

8. Cephalosporins (Manufactured in Dedicated Cephalosporin Block)
   - Cefixime
   - Cefpodoxime
   - Cefuroxime

CATEGORY C: ANTI-INFECTIVES (NON-BETA-LACTAM)

9. Macrolides
   - Azithromycin
   - Clarithromycin
   - Erythromycin

10. Fluoroquinolones
    - Ciprofloxacin
    - Ofloxacin
    - Levofloxacin

11. Antiparasitics
    - Albendazole
    - Ivermectin

================================================================================

LICENSED CAPACITY:

Total Annual Production Capacity: 2.4 Billion Tablets/Capsules

Breakdown by Dosage Form:
- Film-coated Tablets:     1.2 billion units
- Uncoated Tablets:        0.4 billion units
- Hard Gelatin Capsules:   0.6 billion units
- Enteric-coated Tablets:  0.2 billion units

Breakdown by Facility Section:
- Non-Beta-Lactam Block:   2.0 billion units
- Penicillin Block:        0.25 billion units
- Cephalosporin Block:     0.15 billion units

================================================================================

SCHEDULE M COMPLIANCE REQUIREMENTS:

The licensee shall comply with the Good Manufacturing Practices as specified
in Schedule M of the Drugs and Cosmetics Rules, 1945, including but not
limited to:

1. GENERAL REQUIREMENTS
   - Factory premises shall be located away from environmental pollutants
   - Buildings shall be designed to permit manufacturing operations in a
     logical sequence
   - Adequate space for manufacturing, storage, and quality control
   - Premises shall be maintained in good state of repair

2. WAREHOUSING AREA
   - Adequate space for orderly storage of materials and products
   - Quarantine areas for materials awaiting testing
   - Separate area for rejected materials
   - Temperature and humidity controlled as required

3. PRODUCTION AREA
   - Adequate size for logical workflow
   - Air handling systems to prevent cross-contamination
   - Dedicated and self-contained areas for sensitizing products (penicillins)
   - Pressure differentials between areas to be maintained

4. ANCILLARY AREAS
   - Rest and refreshment rooms separate from manufacturing areas
   - Facilities for changing clothes and personal hygiene
   - Toilets not to open directly to production areas

5. QUALITY CONTROL AREA
   - Adequate space for laboratory operations
   - Separate areas for biological, microbiological, and radioisotope testing
   - Adequate storage space for samples and reagents

6. PERSONNEL
   - Adequate number of qualified personnel
   - Training programs for personnel
   - Annual medical examination
   - Specific responsibilities and authorities defined

7. SANITATION
   - Detailed sanitation program in writing
   - Regular pest control
   - Validation of cleaning procedures

8. EQUIPMENT
   - Equipment shall be designed to prevent contamination
   - Equipment shall be constructed of non-reactive materials
   - Calibration at regular intervals
   - Records of maintenance and calibration

9. DOCUMENTATION
   - Site Master File
   - Standard Operating Procedures
   - Batch Manufacturing Records
   - Batch Testing Records
   - Validation documents
   - Training records

10. PRODUCTION
    - Production operations to follow clearly defined procedures
    - In-process controls during manufacture
    - Batch numbering system
    - Packaging and labeling as per approved specifications

11. QUALITY CONTROL
    - Sampling procedures
    - Validated test methods
    - Testing as per approved specifications
    - Out-of-specification investigations
    - Stability studies

================================================================================

CONDITIONS OF LICENSE:

1. The premises shall be used exclusively for the purposes specified in this
   license and shall not be altered without prior permission of the Licensing
   Authority.

2. The Technical Director/Approved Technical Head shall be present at the
   premises during manufacturing hours and shall be responsible for all
   technical operations.

3. No drug shall be manufactured without obtaining prior approval of the
   formulation and process (Form 29 approval).

4. Every batch of drug manufactured shall be tested by the Quality Control
   Department before release and shall be released only if it conforms to
   the approved specifications.

5. Adequate records of all manufacturing and testing operations shall be
   maintained for a period of at least one year after the expiry date of
   the batch.

6. Any adverse drug reaction of a serious nature shall be reported to the
   Licensing Authority within 15 days of receipt of information.

7. The license is non-transferable. Any change in constitution of the firm,
   ownership, or location shall require fresh application.

8. Drugs manufactured under this license shall be sold only to persons
   licensed to sell drugs.

9. The licensee shall permit inspection of the premises by Drug Inspectors
   at any time without prior notice.

10. Drugs specified in Schedule H and H1 shall be sold only on the
    prescription of a Registered Medical Practitioner.

11. Beta-lactam antibiotics (penicillins and cephalosporins) shall be
    manufactured only in the dedicated blocks with separate air handling
    systems and no cross-traffic.

12. The licensee shall maintain a Pharmacovigilance system and report all
    Adverse Drug Reactions to the National Pharmacovigilance Programme.

================================================================================

INSPECTION HISTORY:

Inspection Date    Inspector                Type        Observations   Status
--------------------------------------------------------------------------------
March 10, 2013     Drug Inspector, FDA      Initial     3 Minor        Cleared
                   Maharashtra              Inspection   Observations

June 15, 2015      Asst. Commissioner,      Routine     2 Minor        Cleared
                   FDA Maharashtra                      Observations

April 12, 2018     Drug Inspector,          Routine     Nil            Clean
                   FDA Maharashtra

September 8, 2020  Joint Commissioner,      Complaint   Nil            Cleared
                   FDA Maharashtra          Investigation

April 12, 2021     Drug Inspector,          Routine     3 Minor        Cleared
                   FDA Maharashtra                      Observations

August 5, 2024     Drug Inspector,          Routine     Nil            Clean
                   FDA Maharashtra          Annual

================================================================================

PRODUCT-WISE APPROVALS (FORM 29):

The following products have been approved for manufacture under this license:

S.No.  Product Name                    Approval No.      Approval Date
--------------------------------------------------------------------------------
1.     Amoxicillin 250mg Capsules      MH/29/2014/566   Feb 15, 2014
2.     Amoxicillin 500mg Capsules      MH/29/2014/567   Feb 15, 2014
3.     Metformin HCl 500mg Tablets     MH/29/2014/890   Mar 20, 2014
4.     Metformin HCl 850mg Tablets     MH/29/2014/891   Mar 20, 2014
5.     Metformin HCl 1000mg Tablets    MH/29/2016/892   Jun 10, 2016
6.     Amlodipine 5mg Tablets          MH/29/2014/123   Apr 5, 2014
7.     Amlodipine 10mg Tablets         MH/29/2014/124   Apr 5, 2014
8.     Atorvastatin 10mg Tablets       MH/29/2015/234   Jan 15, 2015
9.     Atorvastatin 20mg Tablets       MH/29/2015/235   Jan 15, 2015
10.    Azithromycin 250mg Tablets      MH/29/2018/234   May 8, 2018
11.    Azithromycin 500mg Tablets      MH/29/2018/235   May 8, 2018
12.    Omeprazole 20mg Capsules        MH/29/2016/456   Aug 12, 2016
13.    Pantoprazole 40mg Tablets       MH/29/2016/789   Sep 20, 2016
14.    Cefixime 200mg Tablets          MH/29/2017/345   Feb 28, 2017
15.    Cefixime 100mg DT               MH/29/2017/346   Feb 28, 2017
...    (Total 47 products approved)

[Complete list maintained in Product Master File at premises]

================================================================================

RENEWAL REQUIREMENTS:

For renewal of this license, the following documents shall be submitted at
least 60 days before expiry:

1. Application in Form 27-D
2. License fee as prescribed
3. Copy of existing license
4. Blueprint of premises (if any changes)
5. List of products manufactured in previous year
6. List of machinery and equipment
7. List of technical staff with qualifications
8. Undertaking to comply with Schedule M
9. Details of any adverse observations in previous inspections
10. Stability data for products manufactured

================================================================================

ACKNOWLEDGEMENT:

This license has been issued subject to the provisions of the Drugs and
Cosmetics Act, 1940 and the rules made thereunder. The licensee is required
to comply with all conditions of the license and the Good Manufacturing
Practices specified in Schedule M.

Non-compliance with the conditions of this license or the provisions of the
Act may result in suspension or cancellation of the license.

                                             [SEAL OF FDA MAHARASHTRA]

                                             Sd/-
                                             Assistant Commissioner of FDA
                                             Food and Drug Administration
                                             Government of Maharashtra

Date of Issue: March 15, 2023

Office Address:
Food and Drug Administration
Government of Maharashtra
MIDC Bhavan, 3rd Floor
Station Road, Thane - 400601

================================================================================
                    END OF DRUG MANUFACTURING LICENSE
================================================================================

================================================================================
                    ADDITIONAL LICENSE: LOAN LICENSE FOR EXPORT
================================================================================

LICENSE NUMBER: MH/20B/2013/5678

This additional license is issued under Form 20-B for manufacture of drugs
exclusively for export purposes.

The conditions applicable to the main license (MH/25D/2013/1234) shall apply
mutatis mutandis to this license.

Products manufactured under this license shall not be sold in India without
separate approval under Form 25-D/28-D license.

Valid Until: March 14, 2028

================================================================================
